The leading compound in Iveric's pipeline is a a C5 inhibitor for geographic atrophy.

'Astellas Pharma agreed to buy US biotech group Iveric Bio for roughly $5.9bn, marking the Japanese drugmaker’s largest-ever acquisition and giving it access to the rapidly expanding market for age-related eye diseases.'

https://www.ft.com/content/fa8b17e0-ea52-4450-8218-d721f76c6d9e